Whether the Simplified Psoriasis Index (SPI), a recently created multidomain instrument for evaluating psoriasis, has utility was ascertained in a study examining response to secukinumab. Patients suffering from moderatetosevere plaque psoriasis were administered secukinumab 300mg subcutaneously once weekly from baseline to W4, then every 4weeks until W48, in an openlabel, multicentre study including 17 French centres. As per findings, reduction of Psoriasis Area and Severity Index (PASI) scores following treatment with secukinumab was shown to be closely correlated with proSPIs (SPI psoriasis severity), supporting the latter's appropriateness for evaluating response to therapy. Despite a slightly weaker correlation between PASI and saSPIs (selfassessed severity), patients were shown to be capable of finishing a valid evaluation of their psoriasis independently, and therefore potentially remotely. With the added advantage of psychosocial impact assessment (SPIp), SPI affords a valid instrument allowing patients to evaluate their own psoriasis, remotely if required.

Excerpt from:

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderatetosevere psoriasis as assessed by the Simplified Psoriasis Index:...